Medicus Pharma Ltd. Announces First Patient Randomized in Phase 2 Trial of SKNJCT-003 for the Treatment of Nodular Basal Cell Carcinoma in Adults
Toronto, Ontario--(Newsfile Corp. - August 27, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") announces the enrollment of the first patient in its Phase 2 clinical trial SKNJCT-003 for the treatment of nodular basal cell carcinoma (nBCC). Clinical Trial Design The clinical study, SKNJCT-003, is designed to be a randomized, double-blind, placebo-controlled (P-MNA), multi-center study enrolling up to 60 subjects presenting with nBCC of the skin. The study will...
2024-08-27 8:36 AM EDT
Medicus Pharma Ltd. Submits Updated Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Toronto, Ontario--(Newsfile Corp. - July 15, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") is pleased to announce the submission of an updated and complete Phase 2 Investigational New Drug (IND) clinical protocol (SKNJCT-003) to the United States Food and Drug Administration (FDA) to non-invasively treat basal cell carcinoma (BCC) of the skin using micro-needle arrays containing doxorubicin (D-MNA), developed by its wholly owned portfolio company, Skinject,...
2024-07-15 7:30 AM EDT
Medicus Pharma Ltd. Announces Closing of Non-Brokered Private Placement of Common Shares and Conversion of Convertible Notes
Toronto, Ontario--(Newsfile Corp. - July 5, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it has completed its previously announced non-brokered private placement (the "Equity Offering") of 2,922,500 common shares of the Company ("Shares"), at an issuance price of US$2.00 per Share, for aggregate gross proceeds of US$5,845,000. The Company paid US$375,000 of finders' fees in connection with the Equity Offering. The Equity Offering closed into...
2024-07-05 7:30 AM EDT
Medicus Pharma Ltd. Announces Proposed Non-Brokered Private Placement of Common Shares and Conversion of Convertible Notes
Toronto, Ontario--(Newsfile Corp. - June 26, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it intends to complete a non-brokered private placement (the "Equity Offering") of 2,922,500 common shares of the Company ("Shares"), at an issuance price of US$2.00 per Share, for aggregate gross proceeds of US$5,845,000. The Company expects to pay US$375,000 of finders' fees in connection with the Equity Offering. The closing of the Equity Offering is...
2024-06-26 6:00 PM EDT
Medicus Pharma Ltd. Announces Filing of Registration Statement for Proposed Initial Public Offering in the United States
Toronto, Ontario--(Newsfile Corp. - May 29, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it has publicly filed a registration statement on Form F-1 (the "Registration Statement") with the U.S. Securities and Exchange Commission (the "SEC") relating to a proposed initial public offering of its securities in the United States. The proposed offering is for units consisting of common shares and warrants and the Company intends to list its common...
2024-05-29 7:00 AM EDT
Medicus Pharma Ltd. Announces Closing of Private Placement of Convertible Notes
Toronto, Ontario--(Newsfile Corp. - May 3, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it has completed the first closing of its previously announced private placement (the "Private Placement") of 10.00% Unsecured Convertible Notes due 2025 (the "Notes"). The Company issued US$5,172,500 aggregate principal amount of Notes in the first closing, which was unbrokered. The Company may issue additional Notes in one or more further closings, with...
2024-05-03 6:00 PM EDT
Medicus Pharma Ltd. Announces Proposed Private Placement of Convertible Notes
Toronto, Ontario--(Newsfile Corp. - April 25, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce that it intends to complete the first closing of a private placement (the "Private Placement") of its 10.00% Unsecured Convertible Notes due 2025 (the "Notes"). Approximately US$5,172,500 aggregate principal amount of Notes will be issued at the first closing, which is expected to occur on or about May 1st , 2024, subject to customary closing conditions,...
2024-04-25 3:07 PM EDT
Medicus Pharma Ltd. Receives FDA Comments on Phase 2 Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Toronto, Ontario--(Newsfile Corp. - March 21, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) (the "Company") is pleased to announce the receipt of comments from the U.S Food and Drug Administration (FDA). The clinical non-hold comments from the FDA consider the results of the study exploratory and request the Company to provide data from clinical studies (SKNJCT-001) to support the dose of 100μg and 200μg of micro-array needles containing doxorubicin (D-MNA). FDA has also requested the...
2024-03-21 7:30 AM EDT
Medicus Pharma Ltd. Announces Appointment of Erica Monaco as Chief Operating Officer
Toronto, Ontario--(Newsfile Corp. - March 5, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") is pleased to announce the appointment of Erica Monaco as Chief Operating Officer. Ms. Monaco is an accomplished C-suite professional with a successful track record as a leader in the pharmaceutical industry. She has spent the last decade in the dermatology sector with an extensive track record of building start-up operations, accelerating change, and driving process...
2024-03-05 7:30 AM EST
Medicus Pharma Ltd. Publishes Phase 1 Clinical Study Report Demonstrating Safety & Tolerability in All Participants with Basal Cell Carcinoma
Toronto, Ontario--(Newsfile Corp. - February 15, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") is pleased to announce that it has published the abbreviated clinical study report (CSR) from the SKNJCT-001 Phase 1 safety and tolerability study. SKNJCT-001 is an open-label, dose-escalation, placebo-controlled trial to evaluate dose limiting toxicity (DLT), maximum tolerated dose (MTD), safety and tolerability of dissolvable microneedle arrays loaded with the...
2024-02-15 7:30 AM EST
Medicus Pharma Ltd. Announces the Filing of a Final Base Shelf Prospectus
Toronto, Ontario--(Newsfile Corp. - January 25, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) ("Medicus" or the "Company") has filed a final short form base shelf prospectus (the "Shelf Prospectus") with the securities regulatory authorities in each of the provinces and territories of Canada. The Shelf Prospectus allows Medicus to offer from time to time over a 25-month period up to US$50 million (or the equivalent in other currencies) of common shares, preferred shares, warrants, subscription...
2024-01-25 5:30 PM EST
Medicus Pharma Ltd. Announces Listing on Frankfurt Stock Exchange
Toronto, Ontario--(Newsfile Corp. - January 18, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) (FSE: N46) ("Medicus" or the "Company") is pleased to announce the listing of its common shares on the Frankfurt Stock Exchange under identification number (WKN) "A3ES6P" and ticker symbol "N46". The Company's common shares continue to be listed on the TSX Venture Exchange under the symbol "MDCX". For further information contact: Carolyn Bonner, President (610) 636-0184 cbonner@medicuspharma.com LHA...
2024-01-18 7:55 AM EST
Medicus Pharma Ltd. Submits to the FDA Phase 2 IND Clinical Protocol to Non-Invasively Treat Basal Cell Carcinoma of the Skin
Toronto, Ontario--(Newsfile Corp. - January 3, 2024) - Medicus Pharma Ltd. (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce the submission to the United States Food and Drug Administration (FDA) a Phase 2 Investigational New Drug (IND) clinical protocol (SKNJCT-003) to non-invasively treat basal cell Carcinoma (BCC) of the skin using micro-array needles containing doxorubicin (D-MNA), developed by its wholly-owned portfolio company, SkinJect, Inc. The company is seeking...
2024-01-03 7:30 AM EST
Medicus Pharma Ltd. to Ring the Toronto Stock Exchange Opening Bell on Thursday October 26th 2023; Appoints Paul A. Marchetto, MD, FACS as Chairman of the Scientific Advisory Board
Toronto, Ontario--(Newsfile Corp. - October 25, 2023) - Medicus Pharma Ltd. (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce that Executive Chairman and CEO Dr. Raza Bokhari, along with the members of the Company's Board of Directors, members of the leadership team, investors, advisors and other stakeholders, will ring the Toronto Stock Exchange (TSX) opening bell on Thursday, October 26th 2023, at 9:30 am ET. The Opening Bell Ringing Ceremony will be held at the TSX Market...
2023-10-25 7:30 AM EDT
Medicus Pharma Ltd. Announces Appointment of Huma Qamar, MD as Chief Scientific Officer & Head of R&D Program
Toronto, Ontario--(Newsfile Corp. - October 18, 2023) - Medicus Pharma Ltd. (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce the appointment of Huma Qamar, MD as the Chief Scientific Officer & Head of R&D Program. Dr. Qamar has worked in the clinical research field for some of the most renowned Ivy league institutions such as Yale University, Harvard University and the University of Pennsylvania. She has robust experience in developing Phase I-IV clinical protocols and...
2023-10-18 7:30 AM EDT
Medicus Pharma Ltd. Announces Commencement of Trading on TSX Venture Exchange and Appointment of Seasoned Pharma Executive Barry Fishman to the Board of Directors
Toronto, Ontario--(Newsfile Corp. - October 11, 2023) - Medicus Pharma Ltd. (TSXV: MDCX) ("Medicus" or the "Company") is pleased to announce that it will commence trading on the TSX Venture Exchange on October 11th, 2023. The initial trading price is CDN $2.75. The Company also announced that Barry Fishman, a seasoned pharma executive has joined the Company's board of directors as an independent director. Mr. Fishman was recently appointed as Chief Corporate Development Officer of Apotex Inc....
2023-10-11 8:39 AM EDT
Medicus Pharma Ltd. Announces Closing of Business Combination
Toronto, Ontario--(Newsfile Corp. - October 2, 2023) - Medicus Pharma Ltd. (TSXV: MDCX) (formerly known as Interactive Capital Partners Corporation, "Medicus" or the "Company") is pleased to announce that it has completed its previously announced business combination (the "Business Combination") with SkinJect, Inc., a company existing under the laws of Pennsylvania ("SkinJect"). The Business Combination was completed pursuant to a business combination agreement dated May 12, 2023, as amended...
2023-10-02 4:36 PM EDT
Interactive Capital Partners Corporation Announces Filing of Final Non-Offering Prospectus
Vancouver, British Columbia--(Newsfile Corp. - September 22, 2023) - Interactive Capital Partners Corporation (the "Company") is pleased to announce that it has filed with the relevant Canadian securities administrators a final non-offering prospectus in connection with its previously announced business combination (the "Business Combination") with SkinJect, Inc., a company existing under the laws of the Commonwealth of Pennsylvania ("SkinJect"). Upon completion of the Business Combination,...
2023-09-22 12:30 PM EDT
Interactive Capital Partners Announces Appointment of Director
Toronto, Ontario--(Newsfile Corp. - June 1, 2021) - Interactive Capital Partners Corporation (the "Company") announces the resignation of Ms. Jessica Whitton as a director of the Company, effective immediately. The Company wishes to thank Ms. Whitton for her contribution to the Company and wishes her all the best in her future endeavors. The Company is pleased to announce the appointment of Mr. Chris Irwin as a director of the Company. Mr. Irwin practices securities and corporate/commercial...
2021-06-01 6:27 PM EDT
Interactive Capital Partners Corporation Announces Debt Settlement
Toronto, Ontario--(Newsfile Corp. - February 9, 2021) - Interactive Capital Partners Corporation (the "Company") announces that it has agreed to settle an aggregate of $300,000 of indebtedness owed to certain arm's length and non-arm's length creditors through the issuance of an aggregate of 6,000,000 common shares ("Common Shares") of the Company at a price of $0.05 per Common Share (the "Debt Settlement"). All Common Shares issued in connection with the Debt Settlement are subject to a...
2021-02-09 4:54 PM EST